The estimated Net Worth of Julianbaker Bros. Advisors ... is at least $2.72 million dollars as of 13 February 2015. Julianbaker Advisors owns over 5,333,333 units of Idera Pharmaceuticals stock worth over $2,719,258 and over the last 11 years Julianbaker sold IDRA stock worth over $0.
Julianbaker has made over 1 trades of the Idera Pharmaceuticals stock since 2015, according to the Form 4 filled with the SEC. Most recently Julianbaker bought 5,333,333 units of IDRA stock worth $19,999,999 on 13 February 2015.
The largest trade Julianbaker's ever made was buying 5,333,333 units of Idera Pharmaceuticals stock on 13 February 2015 worth over $19,999,999. On average, Julianbaker trades about 355,556 units every 0 days since 2014. As of 13 February 2015 Julianbaker still owns at least 6,323,855 units of Idera Pharmaceuticals stock.
You can see the complete history of Julianbaker Advisors stock trades at the bottom of the page.
Over the last 17 years, insiders at Idera Pharmaceuticals have traded over $20,746,904 worth of Idera Pharmaceuticals stock and bought 38,459,430 units worth $53,771,070 . The most active insiders traders include Bros. Advisors Lp14159, L.P..., Bros. Advisors Lp Baker Bro... et Invest Corp Pillar Pharmace.... On average, Idera Pharmaceuticals executives and independent directors trade stock every 43 days with the average trade being worth of $309,429. The most recent stock trade was executed by John J. Kirby on 17 December 2021, trading 10,000 units of IDRA stock currently worth $6,200.
Harnessing the approach of the earliest researchers in immunotherapy and the company's vast experience in developing proprietary immunology platforms, Idera's development program is focused on priming the immune system to play a more powerful role in fighting cancer, ultimately increasing the number of people who can benefit from immunotherapy. Idera also continues to focus on the acquisition, development, and ultimate commercialization of drug candidates for both oncology and rare disease indications characterized by small, well-defined patient populations with serious unmet needs.
Idera Pharmaceuticals executives and other stock owners filed with the SEC include: